Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Pediatric Brain Tumor Consortium
Modality
other_biological
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02031965CT.gov Oncolytic HSV-1716 in Treating Younger Patients With Refractory or Recurrent High Grade Glioma That Can Be Removed By Surgery | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Gliomatosis Cerebri
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Seprehvir (this asset) | Pediatric Brain Tumor Consortium | P1 | CC · 43 |
| Valproic Acid | University of Göttingen | P3 | B |
| Adriamycin | Meyer Children's Hospital IRCCS | P2 | CCC |
| Palbociclib | Pediatric Brain Tumor Consortium | P1 | CC |
| Onc 206 | Jazz Pharmaceuticals | P1 | CC |
| Dexasone | Pediatric Brain Tumor Consortium | P1 | CC |
| FDOPA | Erik Mittra | N/A | D |
| Gefitinib | National Cancer Institute (NCI) | P1/2 | NR |
Other indications for Seprehvir
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Clivus Chordoma | — | P1 | CC · 47 |
| Malignant Peripheral Nerve Sheath Tumor | — | P1 | CC · 47 |
| Neoplasm | — | P1 | CC · 47 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Seprehvir in Gliomatosis Cerebri. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/hsv-1716-gliomatosis-cerebri
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →